Adipose tissue‐derived FABP4 mediates glucagon‐stimulated hepatic glucose production in gestational diabetes
Diabetes, Obesity and Metabolism · 2023
DOI: 10.1111/dom.15214 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2023. Verfasst von Idit Ron und 9 weiteren Autor:innen. Beteiligte Einrichtung: The Dalia and David Arabov Endocrinology and Diabetes Research Center, Division of Endocrinology, Diabetes and Metabolism, Sheba Medical Center, Tel-…. Hauptthemen laut MEDLINE: Diabetes, Gestational, Fatty Acid-Binding Proteins, Insulin Resistance. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Israel Science Foundation.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
One of the most common complications of pregnancy is gestational diabetes mellitus (GDM), which may result in significant health threats of the mother, fetus and the newborn. Fatty acid‐binding protein 4 (FABP4) is an adipokine that regulates glucose homeostasis by promoting glucose production and liver insulin resistance in mouse models. FABP4 levels are increased in GDM and correlates with maternal indices of insulin resistance, with a rapid decline post‐partum. We therefore aimed to determine the tissue origin of elevated circulating FABP4 levels in GDM and to assess its potential contribution in promoting glucagon‐induced hepatic glucose production. Materials and Methods FABP4 protein and gene expression was determined in biopsies from placenta, subcutaneous (sWAT) and visceral (vWAT) white adipose tissues from GDM and normoglycaemic pregnant women. FABP4 differential contribution in glucagon‐stimulated hepatic glucose production was tested in conditioned media before and after its immune clearance.
Results
We showed that FABP4 is expressed in placenta, sWAT and vWAT of pregnant women at term, with a significant increase in its secretion from vWAT of women with GDM compared with normoglycaemic pregnant women. Neutralizing FABP4 from both normoglycaemic pregnant women and GDM vWAT secretome, resulted in a decrease in glucagon‐stimulated hepatic glucose production.
Conclusions
This study provides new insights into the role of adipose tissue‐derived FABP4 in GDM, highlighting this adipokine, as a potential co‐activator of glucagon‐stimulated hepatic glucose production during pregnancy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Dalia and David Arabov Endocrinology and Diabetes Research Center, Division of Endocrinology, Diabetes and Metabolism, Sheba Medical Center, Tel-Hashomer, Israel.
- Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
- Department of Obstetrics and Gynecology, Sheba Medical Center, Tel-Hashomer, Israel.
- Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA.
- Department of Gynecologic Oncology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
ORCID-Profile: Idit Ron, Amir Tirosh
Förderung
- Israel Science Foundation
Zitieren
APA
Ron, I., Mdah, R., Zemet, R., Ulman, R. Y., Rathaus, M., Brandt, B., Mazaki-Tovi, S., Hemi, R., Barhod, E., & Tirosh, A. (2023). Adipose tissue‐derived FABP4 mediates glucagon‐stimulated hepatic glucose production in gestational diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15214
Vancouver
Ron I, Mdah R, Zemet R, Ulman RY, Rathaus M, Brandt B, et al. Adipose tissue‐derived FABP4 mediates glucagon‐stimulated hepatic glucose production in gestational diabetes. Diabetes, Obesity and Metabolism. 2023. doi:10.1111/dom.15214
BibTeX
@article{Ron2023,
author = {Ron, Idit and Mdah, Ragad and Zemet, Roni and Ulman, Rakefet Yoeli and Rathaus, Moran and Brandt, Benny and Mazaki-Tovi, Shali and Hemi, Rina and Barhod, Ehud and Tirosh, Amir},
title = {Adipose tissue‐derived FABP4 mediates glucagon‐stimulated hepatic glucose production in gestational diabetes},
journal = {Diabetes, Obesity and Metabolism},
year = {2023},
doi = {10.1111/dom.15214}
}
EUVIMED